ResultsIQ

ResultsIQ › Latest results › Sahajanand Medical Technologies Limited

Sahajanand Medical Technologies Limited Q2 FY27 results deck summary

NSE: SMT · BSE: 545001

Results deck of 5 Nov 2026, summarised by AI from the filing.

Q2 FY27 revenue rose 24.7% to ₹3,734 mn with EBITDA up 36.6% to ₹656 mn and PAT up 26.6% to ₹265 mn, the highest-ever quarter.

Key takeaways

  1. Record quarter Q2 FY27 revenue was ₹3,734 mn (+24.7% YoY), EBITDA ₹656 mn (+36.6%) and PAT ₹265 mn (+26.6%), the highest-ever quarterly figures.
  2. No numeric guidance Management gave no numeric revenue or margin guidance, only priorities of richer product mix, vertical integration, plant utilisation and overhead control.
  3. Cash cycle The cash conversion cycle fell 16 days to 128 in H1 FY27 from 144 in FY25, on faster collections and leaner stock.
  4. RoW growth RoW revenue grew 37.1% YoY to ₹2,904 mn in H1 FY27, now 40.0% of revenue and the largest region.

Original filing on BSE

Sahajanand Medical Technologies Limited Q2 FY27 results

As filed: Revenue ₹373 cr, EBITDA ₹65.6 cr, PAT ₹26.5 cr, EBITDA margin 17.6%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹373 cr). Scored once a year-earlier consolidated quarter exists.

Sahajanand Medical Technologies Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.